Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NBIX – Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc.
NBIX
$128.91
Name : Neurocrine Biosciences, Inc.
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $12,785,487,872.00
EPSttm : 3.38
finviz dynamic chart for NBIX
Neurocrine Biosciences, Inc.
$128.91
0.53%
$0.68

Float Short %

3.39

Margin Of Safety %

-6

Put/Call OI Ratio

0.7

EPS Next Q Diff

0.82

EPS Last/This Y

2.69

EPS This/Next Y

2.24

Price

128.91

Target Price

167.8

Analyst Recom

1.34

Performance Q

20.94

Relative Volume

1.24

Beta

0.25

Ticker: NBIX




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04NBIX129.110.600.176135
2025-07-07NBIX127.860.600.006131
2025-07-08NBIX128.740.590.366153
2025-07-09NBIX133.630.590.076199
2025-07-10NBIX134.980.590.096242
2025-07-11NBIX133.450.580.386313
2025-07-14NBIX135.120.580.096317
2025-07-15NBIX131.240.580.416338
2025-07-16NBIX133.810.640.506723
2025-07-17NBIX134.70.640.326733
2025-07-18NBIX131.980.660.327127
2025-07-21NBIX131.790.730.445921
2025-07-22NBIX132.660.720.026072
2025-07-23NBIX133.60.660.036414
2025-07-24NBIX131.430.630.026573
2025-07-25NBIX132.010.620.976676
2025-07-28NBIX133.730.640.787284
2025-07-29NBIX134.190.651.777331
2025-07-30NBIX136.750.660.177424
2025-07-31NBIX128.230.594.338431
2025-08-01NBIX128.840.700.189490
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04NBIX129.11-8.3125.16.10
2025-07-07NBIX127.76-8.3119.46.10
2025-07-08NBIX128.74-8.3131.26.10
2025-07-09NBIX133.51-8.3151.96.10
2025-07-10NBIX134.92-8.3133.86.10
2025-07-11NBIX133.46-8.3126.36.10
2025-07-14NBIX135.13-8.3135.16.10
2025-07-15NBIX131.24-8.3106.96.10
2025-07-16NBIX133.55-8.3138.66.10
2025-07-17NBIX134.11-8.3129.86.10
2025-07-18NBIX132.01-8.3115.96.10
2025-07-21NBIX131.82-8.3125.66.10
2025-07-22NBIX132.71-8.3131.16.10
2025-07-23NBIX133.66-8.3131.36.10
2025-07-24NBIX131.64-9.8116.26.07
2025-07-25NBIX132.14-9.8129.26.07
2025-07-28NBIX133.95-9.8136.06.07
2025-07-29NBIX134.19-9.8129.06.07
2025-07-30NBIX136.76-9.8139.76.07
2025-07-31NBIX128.23-7.784.06.09
2025-08-01NBIX128.91-7.7132.56.09
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04NBIX-8.190.603.66
2025-07-07NBIX-8.680.593.66
2025-07-08NBIX-8.680.593.66
2025-07-09NBIX-8.680.593.66
2025-07-10NBIX-8.680.593.66
2025-07-11NBIX-10.070.593.70
2025-07-14NBIX-10.070.883.70
2025-07-15NBIX-10.070.883.70
2025-07-16NBIX-10.070.883.70
2025-07-17NBIX-10.070.883.70
2025-07-18NBIX-8.550.883.70
2025-07-21NBIX-8.55-0.243.70
2025-07-22NBIX-8.55-0.243.70
2025-07-23NBIX-8.55-0.243.70
2025-07-24NBIX-8.55-0.243.70
2025-07-25NBIX-8.55-0.243.39
2025-07-28NBIX-8.55-0.823.39
2025-07-29NBIX-8.55-0.823.39
2025-07-30NBIX-4.92-0.823.39
2025-07-31NBIX-4.92-0.823.39
2025-08-01NBIX-4.92-0.823.39
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

1.06

Avg. EPS Est. Current Quarter

1.5

Avg. EPS Est. Next Quarter

1.88

Insider Transactions

-4.92

Institutional Transactions

-0.82

Beta

0.25

Average Sales Estimate Current Quarter

653

Average Sales Estimate Next Quarter

716

Fair Value

121.47

Quality Score

77

Growth Score

99

Sentiment Score

49

Actual DrawDown %

18.4

Max Drawdown 5-Year %

-42.9

Target Price

167.8

P/E

38.05

Forward P/E

19.81

PEG

1.04

P/S

5.09

P/B

4.74

P/Free Cash Flow

24.18

EPS

3.39

Average EPS Est. Cur. Y​

6.09

EPS Next Y. (Est.)

8.33

Target Price Estimates Raised

2

Target Price Estimates Lowered

Profit Margin

13.88

Relative Volume

1.24

Return on Equity vs Sector %

-10.8

Return on Equity vs Industry %

5.1

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

132.5
Neurocrine Biosciences, Inc.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 1800
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
stock quote shares NBIX – Neurocrine Biosciences, Inc. Stock Price stock today
news today NBIX – Neurocrine Biosciences, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch NBIX – Neurocrine Biosciences, Inc. yahoo finance google finance
stock history NBIX – Neurocrine Biosciences, Inc. invest stock market
stock prices NBIX premarket after hours
ticker NBIX fair value insiders trading